Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced parkinsonian symptoms, predominantly bradykinesia and tremor, in marmosets. These symptoms were reduced by L-DOPA plus benserazide but the putative D1-receptor agonist SKF 38393-A did not affect tremor and increased the bradykinesia. Neither treatment affected behaviour in normal marmosets. It is suggested that D1-receptor agonists are unlikely to be effective in the treatment of Parkinson's disease.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000818:Animals; D001522:Behavior, Animal; D001545:Benserazide / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use*; D002143:Callitrichinae; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D009069:Movement Disorders / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D011725:Pyridines; D014202:Tremor / Q000188:drug therapy
D001552:Benzazepines; D011725:Pyridines; D007980:Levodopa; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D001545:Benserazide; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine